MASKd: a Study on Kawasaki Disease (KD) Complicated by Macrophage Activation Syndrome (MAS)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age4-17
SponsorMeyer Children's Hospital IRCCS
About this trial
Kawasaki Disease (KD) is one of the most common vasculitides in childhood and represents a leading cause of acquired heart disease in developed countries. Macrophage Activation Syndrome (MAS) is a potentially life threatening hyperinflammatory condition belonging to the spectrum of hemophagocytic lymphohistiocytosis (HLH), and it can complicate various rheumatologic diseases. Awareness of MAS in the context of KD has recently increased, supporting the hypothesis that it is an underdiagnosed complication. The study aims to define the epidemiology, clinical characteristics, management, and therapeutic strategies of MAS in patients with KD, through a multicenter data collection in Europe.
Eligibility criteria
Qualifiers
Age between 4 weeks and under 18 years at the time of KD diagnosis
Diagnosis of KD made according to the 2024 AHA guidelines
Diagnosis of MAS made by the attending physician within 30 days from the onset of KD.
Disqualifiers
Unconfirmed diagnosis of KD (e.g., mimicking conditions)
Primary (genetic) HLH
Lack of informed consent
MAS diagnosed more than 30 days after or more than 15 days before the onset of KD
Trial design
Treatments tested in this trial
- Not listed
Trial groups
150 Participants
are grouped into 3 trial groupsSponsors and collaborators
Source ClinicalTrials.gov